Loading…
ACADIA Pharmaceuticals Inc. is projected to rise to $26.52 by 2027, a +25% move from its current price of $21.19. ACAD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $20.81 | $21.18 | $21.56 | -0.04% |
| May 30 | $20.65 | $21.17 | $21.71 | -0.08% |
| May 31 | $20.52 | $21.17 | $21.83 | -0.12% |
| Jun 1 | $20.42 | $21.16 | $21.92 | -0.15% |
| Jun 2 | $20.32 | $21.15 | $22.01 | -0.19% |
| Jun 3 | $20.24 | $21.14 | $22.08 | -0.23% |
| Jun 4 | $20.16 | $21.13 | $22.15 | -0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $20.16 | $21.13 | $22.15 | -0.27% |
| Week 2 | $19.72 | $21.08 | $22.53 | -0.54% |
| Week 3 | $19.37 | $21.02 | $22.81 | -0.81% |
| Week 4 | $19.08 | $20.96 | $23.03 | -1.07% |
| Week 5 | $18.82 | $20.91 | $23.23 | -1.34% |
| Week 6 | $18.58 | $20.85 | $23.40 | -1.60% |
| Week 7 | $18.36 | $20.79 | $23.55 | -1.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for neurological and rare diseases in North America. Its portfolio includes NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
The company also develops remlifanserin (phase 2 for Alzheimer’s disease psychosis and Lewy body dementia psychosis); ACP-211 (phase 2 for major depressive disorder); ACP-711 (phase I for essential tremor); and ACP-271, a GPR88 agonist in phase I for tardive dyskinesia and Huntington’s disease, along with ACP-2591 (phase 1 for Rett syndrome and fragile X syndrome) and STOKE Antisense Oligonucleotide Program in discovery for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and a license/collaboration with Stoke Therapeutics to discover, develop, and commercialize RNA-based medicines for severe and rare CNS diseases. The company was formerly Receptor Technologies, Inc.
and changed its name to ACADIA Pharmaceuticals Inc. in 1997, after being incorporated in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc. (ACAD) is a healthcare company in the biopharmaceutical sector focused on medicines for neurological and rare diseases. The stock is currently priced at $21.10 with a market capitalization of $3.61B and a rank of 1584.
The current price and market position are complemented by a multi-year forecast showing a progression from neutral in 2026 to bullish in later years. This landscape suggests an evolving long-term growth trajectory despite near-term volatility.
A major floor 9.1% below — a decisive break under it would weaken the trend.
The nearest floor, 3.4% below — buyers have tended to step in here.
The nearest ceiling, 7.0% above — a clean break opens room to run.
A major ceiling 29.8% above — clearing it would confirm fresh momentum.
Key ACAD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACAD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.16 | Buy | $21.18 | Buy |
| MA 10 | $21.27 | Sell | $21.30 | Sell |
| MA 20 | $21.69 | Sell | $21.52 | Sell |
| MA 50 | $21.71 | Sell | $21.98 | Sell |
| MA 100 | $23.11 | Sell | $22.58 | Sell |
| MA 200 | $23.61 | Sell | $22.63 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.35 | Neutral |
| Stoch RSI (14) | 47.90 | Neutral |
| CCI (20) | -62.38 | Neutral |
| Williams %R (14) | -65.87 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -5.40 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 34.13 | Neutral |
| TRIX (15) | -0.12 | Sell |
| Awesome (5,34) | -0.66 | Sell |
| Ultimate (7,14,28) | 46.47 | Neutral |
| Momentum (10) | -0.53 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 21.24 | Sell |
| ADX (14) | 9.24 | Neutral |
| ATR (14) | 0.37 | Info |
Technical sentiment is BEARISH with RSI(14) at 40. The price trades near key moving averages, with SMA50 at $21.70 and SMA200 at $23.64. Support is pegged at $20.48 and resistance at $22.67. Over the next 30 days, the price range spans from a low of $18.63 to a high of $23.90, signaling continued volatility in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $20.32 | $21.19 | $26.90 | 0% | Neutral | |
| $21.66 | $26.52 | $33.98 | +25% | Bullish | |
| $23.64 | $29.47 | $38.74 | +39% | Bullish | |
| $24.96 | $31.58 | $42.39 | +49% | Bullish | |
| $26.44 | $33.90 | $46.30 | +60% | Bullish | |
| $26.58 | $34.50 | $47.85 | +63% | Bullish | |
| $28.69 | $37.65 | $52.96 | +78% | Bullish | |
| $32.26 | $42.77 | $60.94 | +102% | Bullish | |
| $36.24 | $48.52 | $69.95 | +129% | Bullish | |
| $40.20 | $54.33 | $79.18 | +156% | Bullish | |
| $53.12 | $74.87 | $114.32 | +253% | Bullish | |
| $83.94 | $126.87 | $207.60 | +499% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $20.32 | $21.19 | $24.77 | +0.00% |
| June 2026 | $17.72 | $20.67 | $24.58 | -2.45% |
| July 2026 | $17.44 | $20.46 | $24.56 | -1.02% |
| August 2026 | $17.68 | $20.84 | $25.20 | +1.87% |
| September 2026 | $17.54 | $20.75 | $25.24 | -0.43% |
| October 2026 | $17.24 | $20.47 | $25.03 | -1.37% |
| November 2026 | $17.67 | $21.03 | $25.84 | +2.77% |
| December 2026 | $18.26 | $21.80 | $26.90 | +3.64% |
Click any year to see its month-by-month ACAD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ACAD price prediction for 2026 points to an average of $21.19 (low $20.32, high $26.90) — a potential gain of 0% on today's $21.19. Price action looks broadly range-bound.
In 2027, ACAD is projected to trade between $21.66 and $33.98, averaging $26.52 — a potential gain of +25% from today's $21.19. That is up +25% on the projected 2026 average. Buyers look set to stay in control over this stretch.
ACADIA Pharmaceuticals Inc.'s 2028 outlook centres on $29.47, within a $23.64 to $38.74 range. That is up +11% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, ACAD could reach as high as $42.39, with a base case around $31.58 and support toward $24.96 — roughly +49% from $21.19. Buyers look set to stay in control over this stretch.
Expect ACAD to range from $26.44 to $46.30 through 2030. The $33.90 average target implies a +60% move from current prices. That is up +7% on the projected 2029 average. Momentum favours further upside here.
The ACAD price prediction for 2031 points to an average of $34.50 (low $26.58, high $47.85) — a potential gain of +63% on today's $21.19. Buyers look set to stay in control over this stretch.
In 2032, ACAD is projected to trade between $28.69 and $52.96, averaging $37.65 — a potential gain of +78% from today's $21.19. That is up +9% on the projected 2031 average. Momentum favours further upside here.
ACADIA Pharmaceuticals Inc.'s 2033 outlook centres on $42.77, within a $32.26 to $60.94 range. That is up +14% on the projected 2032 average. That marks a +102% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ACAD could reach as high as $69.95, with a base case around $48.52 and support toward $36.24 — roughly +129% from $21.19. Momentum favours further upside here.
Expect ACAD to range from $40.20 to $79.18 through 2035. The $54.33 average target implies a +156% move from current prices. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ACAD price prediction for 2040 points to an average of $74.87 (low $53.12, high $114.32) — a potential gain of +253% on today's $21.19. Momentum favours further upside here.
In 2050, ACAD is projected to trade between $83.94 and $207.60, averaging $126.87 — a potential gain of +499% from today's $21.19. That is up +69% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACAD today (≈ 47.192072 ACAD) could be worth
$5,987.38
+$4,987.38 (+499%) by 2050 · US Dollar
Based on the average projected ACAD price of $126.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACADwould be worth at today's price.
$1,000 invested in ACAD on May 27, 2025 (≈ 45.065344 ACAD) would be worth
$954.93
-$45.07 (-4.5%) today · 0.95× · US Dollar
Based on a ACAD entry price of $22.19 vs. today's $21.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.95 | $1,011.46 | +1.1% |
| 1 month ago | $22.3 | $950.22 | -5.0% |
| 3 months ago | $24.64 | $859.98 | -14.0% |
| 6 months ago | $25.04 | $846.25 | -15.4% |
| 1 year ago | $22.19 | $954.93 | -4.5% |
| All time (5.0y) ago | $22.35 | $948.1 | -5.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACAD forecast.
Our base-case forecast reaches $42.00 around 2033.
Implied market cap at $42.00: $7.19B
The multi-year forecast paints a bullish trajectory after 2026, moving from neutral to bullish across the horizon. The year-by-year outlook highlights rising averages and ROI as confidence builds. In 2030, the average price is forecast at $33.89 with an ROI of 60.6 and a bullish sentiment.
The forecast continues to strengthen, with 2040 showing an average of $75.59 and an ROI of 258.2, and 2050 at an average of $127.78 with an ROI of 505.6 and bullish sentiment. The path from 2027 onward remains supportive of higher price levels, though these are estimates and not guarantees, subject to clinical, regulatory, and market dynamics.
Tap a question to reveal the answer.
The forecasted average for 2030 is $33.89 with an ROI of 60.6 and a bullish sentiment.
The long-term forecast shows a bullish outlook from 2027 onward, with progressively higher averages and ROIs, though 2026 is neutral and these are estimates, not guarantees.
Yes—the 2030 forecast max is $46.31.
Bearish sentiment with RSI(14) at 40; price around SMA50 ($21.70) and below SMA200 ($23.64); 30-day range from $18.63 to $23.90 with support at $20.48 and resistance at $22.67.
ACADIA Pharmaceuticals Inc. Community Discussion
0Share your ACADIA Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.